An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis

Ilya Gertsman, Joanne Wuu, Melissa McAlonis-Downes, Majid Ghassemian, Karen Ling, Frank Rigo, Frank Bennett, Michael G Benatar, Timothy M. Miller, Sandrine Da Cruz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The discovery of novel biomarkers has emerged as a critical need for therapeutic development in amyotrophic lateral sclerosis (ALS). For some subsets of ALS, such as the genetic superoxide dismutase 1 (SOD1) form, exciting new treatment strategies, such as antisense oligonucleotide- mediated (ASO-mediated) SOD1 silencing, are being tested in clinical trials, so the identification of pharmacodynamic biomarkers for therapeutic monitoring is essential. We identify increased levels of a 7-amino acid endogenous peptide of SOD1 in cerebrospinal fluid (CSF) of human SOD1 mutation carriers but not in other neurological cases or nondiseased controls. Levels of peptide elevation vary based on the specific SOD1 mutation (ranging from 1.1-fold greater than control in D90A to nearly 30-fold greater in V148G) and correlate with previously published measurements of SOD1 stability. Using a mass spectrometry-based method (liquid chromatography-mass spectrometry), we quantified peptides in both extracellular samples (CSF) and intracellular samples (spinal cord from rat) to demonstrate that the peptide distinguishes mutation-specific differences in intracellular SOD1 degradation. Furthermore, 80% and 63% reductions of the peptide were measured in SOD1G93A and SOD1H46R rat CSF samples, respectively, following treatment with ASO, with an improved correlation to mRNA levels in spinal cords compared with the ELISA measuring intact SOD1 protein. These data demonstrate the potential of this peptide as a pharmacodynamic biomarker.

Original languageEnglish (US)
Article numbere122768
JournalJCI Insight
Volume4
Issue number10
DOIs
StatePublished - Jan 1 2019

Fingerprint

Amyotrophic Lateral Sclerosis
Peptides
Cerebrospinal Fluid
Biomarkers
Mutation
Mass Spectrometry
Spinal Cord
Superoxide Dismutase-1
Antisense Oligonucleotides
Therapeutics
Liquid Chromatography
Enzyme-Linked Immunosorbent Assay
Clinical Trials
Amino Acids
Messenger RNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis. / Gertsman, Ilya; Wuu, Joanne; McAlonis-Downes, Melissa; Ghassemian, Majid; Ling, Karen; Rigo, Frank; Bennett, Frank; Benatar, Michael G; Miller, Timothy M.; Da Cruz, Sandrine.

In: JCI Insight, Vol. 4, No. 10, e122768, 01.01.2019.

Research output: Contribution to journalArticle

Gertsman, Ilya ; Wuu, Joanne ; McAlonis-Downes, Melissa ; Ghassemian, Majid ; Ling, Karen ; Rigo, Frank ; Bennett, Frank ; Benatar, Michael G ; Miller, Timothy M. ; Da Cruz, Sandrine. / An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis. In: JCI Insight. 2019 ; Vol. 4, No. 10.
@article{ca60ae0f97f241058a79d3195a1ad5a6,
title = "An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis",
abstract = "The discovery of novel biomarkers has emerged as a critical need for therapeutic development in amyotrophic lateral sclerosis (ALS). For some subsets of ALS, such as the genetic superoxide dismutase 1 (SOD1) form, exciting new treatment strategies, such as antisense oligonucleotide- mediated (ASO-mediated) SOD1 silencing, are being tested in clinical trials, so the identification of pharmacodynamic biomarkers for therapeutic monitoring is essential. We identify increased levels of a 7-amino acid endogenous peptide of SOD1 in cerebrospinal fluid (CSF) of human SOD1 mutation carriers but not in other neurological cases or nondiseased controls. Levels of peptide elevation vary based on the specific SOD1 mutation (ranging from 1.1-fold greater than control in D90A to nearly 30-fold greater in V148G) and correlate with previously published measurements of SOD1 stability. Using a mass spectrometry-based method (liquid chromatography-mass spectrometry), we quantified peptides in both extracellular samples (CSF) and intracellular samples (spinal cord from rat) to demonstrate that the peptide distinguishes mutation-specific differences in intracellular SOD1 degradation. Furthermore, 80{\%} and 63{\%} reductions of the peptide were measured in SOD1G93A and SOD1H46R rat CSF samples, respectively, following treatment with ASO, with an improved correlation to mRNA levels in spinal cords compared with the ELISA measuring intact SOD1 protein. These data demonstrate the potential of this peptide as a pharmacodynamic biomarker.",
author = "Ilya Gertsman and Joanne Wuu and Melissa McAlonis-Downes and Majid Ghassemian and Karen Ling and Frank Rigo and Frank Bennett and Benatar, {Michael G} and Miller, {Timothy M.} and {Da Cruz}, Sandrine",
year = "2019",
month = "1",
day = "1",
doi = "10.1172/jci.insight.122768",
language = "English (US)",
volume = "4",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis

AU - Gertsman, Ilya

AU - Wuu, Joanne

AU - McAlonis-Downes, Melissa

AU - Ghassemian, Majid

AU - Ling, Karen

AU - Rigo, Frank

AU - Bennett, Frank

AU - Benatar, Michael G

AU - Miller, Timothy M.

AU - Da Cruz, Sandrine

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The discovery of novel biomarkers has emerged as a critical need for therapeutic development in amyotrophic lateral sclerosis (ALS). For some subsets of ALS, such as the genetic superoxide dismutase 1 (SOD1) form, exciting new treatment strategies, such as antisense oligonucleotide- mediated (ASO-mediated) SOD1 silencing, are being tested in clinical trials, so the identification of pharmacodynamic biomarkers for therapeutic monitoring is essential. We identify increased levels of a 7-amino acid endogenous peptide of SOD1 in cerebrospinal fluid (CSF) of human SOD1 mutation carriers but not in other neurological cases or nondiseased controls. Levels of peptide elevation vary based on the specific SOD1 mutation (ranging from 1.1-fold greater than control in D90A to nearly 30-fold greater in V148G) and correlate with previously published measurements of SOD1 stability. Using a mass spectrometry-based method (liquid chromatography-mass spectrometry), we quantified peptides in both extracellular samples (CSF) and intracellular samples (spinal cord from rat) to demonstrate that the peptide distinguishes mutation-specific differences in intracellular SOD1 degradation. Furthermore, 80% and 63% reductions of the peptide were measured in SOD1G93A and SOD1H46R rat CSF samples, respectively, following treatment with ASO, with an improved correlation to mRNA levels in spinal cords compared with the ELISA measuring intact SOD1 protein. These data demonstrate the potential of this peptide as a pharmacodynamic biomarker.

AB - The discovery of novel biomarkers has emerged as a critical need for therapeutic development in amyotrophic lateral sclerosis (ALS). For some subsets of ALS, such as the genetic superoxide dismutase 1 (SOD1) form, exciting new treatment strategies, such as antisense oligonucleotide- mediated (ASO-mediated) SOD1 silencing, are being tested in clinical trials, so the identification of pharmacodynamic biomarkers for therapeutic monitoring is essential. We identify increased levels of a 7-amino acid endogenous peptide of SOD1 in cerebrospinal fluid (CSF) of human SOD1 mutation carriers but not in other neurological cases or nondiseased controls. Levels of peptide elevation vary based on the specific SOD1 mutation (ranging from 1.1-fold greater than control in D90A to nearly 30-fold greater in V148G) and correlate with previously published measurements of SOD1 stability. Using a mass spectrometry-based method (liquid chromatography-mass spectrometry), we quantified peptides in both extracellular samples (CSF) and intracellular samples (spinal cord from rat) to demonstrate that the peptide distinguishes mutation-specific differences in intracellular SOD1 degradation. Furthermore, 80% and 63% reductions of the peptide were measured in SOD1G93A and SOD1H46R rat CSF samples, respectively, following treatment with ASO, with an improved correlation to mRNA levels in spinal cords compared with the ELISA measuring intact SOD1 protein. These data demonstrate the potential of this peptide as a pharmacodynamic biomarker.

UR - http://www.scopus.com/inward/record.url?scp=85070660019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070660019&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.122768

DO - 10.1172/jci.insight.122768

M3 - Article

VL - 4

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 10

M1 - e122768

ER -